Climb Bio, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
CLYM$11.74+6.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated State ments of Cash Flows
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(59,851) | $(73,897) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 8,054 | 5,557 |
| Non-cash operating lease expense | 201 | 220 |
| Accretion of discounts on marketable securities, net | (2,274) | (757) |
| Depreciation and amortization expense | 97 | — |
| In-process research and development, related party | — | 51,659 |
| Unrealized foreign currency transaction (gain) loss | 18 | (42) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (816) | 1,942 |
| Other long-term assets | (1,514) | (200) |
| Accounts payable | 1,564 | (963) |
| Accounts payable and accrued liabilities, related party | — | (177) |
| Accrued expenses and other current liabilities | 372 | 1,445 |
| Operating lease liabilities | (207) | (327) |
| Long-term liabilities | — | (22) |
| Net cash used in operating activities | (54,356) | (15,562) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (186) | — |
| Purchases of marketable securities | (108,078) | (132,197) |
| Maturities of marketable securities | 111,097 | 20,750 |
| Issuance of promissory loan in connection with asset acquisition | — | (5,000) |
| Cash paid in connection with asset acquisition, net of cash received | — | (4,645) |
| Net cash provided by (used in) investing activities | 2,833 | (121,092) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 65 | 10,979 |
| Pre-funded warrant issuance costs | (86) | — |
| Proceeds from issuance of common stock in private placement, net of issuance costs | — | 119,750 |
| Net cash provided by (used in) financing activities | (21) | 130,729 |
| Effect of exchange rate changes on cash and cash equivalents | — | 42 |
| Net change in cash and cash equivalents | (51,544) | (5,883) |
| Cash and cash equivalents at beginning of period | 87,229 | 93,112 |
| Cash and cash equivalents at end of period | $35,685 | $87,229 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Issuance of common stock in exchange for in-process research and development | $— | $41,867 |
| Settlement of promissory loan in connection with asset acquisition | $— | $5,036 |
CLIMB BIO, INC
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.